Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAmortizatization of IntangiblesAsset Writedowns and ImpairmentAsset Writedowns and ImpairmentCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Depreciation and DepletionDepreciation and DepletionFree Cash FlowFree Cash FlowNet Cash FlowNet Cash FlowNet IncomeOther Working Capital ChangesOther Working Capital ChangesOther financing activitiesOther financing activitiesShare-based CompensationShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Share-based Compensation (2019 - 2026)

C4 Therapeutics has reported Share-based Compensation over the past 8 years, most recently at $2.7 million for Q1 2026.

  • For Q1 2026, Share-based Compensation fell 51.5% year-over-year to $2.7 million; the TTM value through Mar 2026 reached $16.3 million, down 43.83%, while the annual FY2025 figure was $19.1 million, 35.61% down from the prior year.
  • Share-based Compensation for Q1 2026 was $2.7 million at C4 Therapeutics, down from $4.0 million in the prior quarter.
  • Over five years, Share-based Compensation peaked at $8.9 million in Q1 2022 and troughed at $2.7 million in Q1 2026.
  • A 5-year average of $6.4 million and a median of $6.4 million in 2023 define the central range for Share-based Compensation.
  • Biggest five-year swings in Share-based Compensation: skyrocketed 132.46% in 2022 and later tumbled 51.5% in 2026.
  • Year by year, Share-based Compensation stood at $6.9 million in 2022, then decreased by 8.09% to $6.4 million in 2023, then increased by 29.5% to $8.2 million in 2024, then tumbled by 51.34% to $4.0 million in 2025, then plummeted by 33.34% to $2.7 million in 2026.
  • Business Quant data shows Share-based Compensation for CCCC at $2.7 million in Q1 2026, $4.0 million in Q4 2025, and $4.6 million in Q3 2025.